Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Hldgs is in a strong position with their divestment of non-Rolvedon assets to Cosette for an upfront payment of $35M plus potential earnouts related to certain product milestones at a low multiple of <1x historical one-year sales. This allows the company to focus on their core products in the oncology market, while also having the opportunity for additional revenue through the CVR attached to the Sprix-related milestones. The 20-day "window-shop" period also provides potential for a superior bid, but given the limited potential for other bidders, we do not anticipate this leading to a protracted bidding war.

Bears say

Assertio Hldgs is facing challenges with its products in the competitive oncology market and is at risk of not achieving its potential potential. Additionally, the company's decision to sell non-Rolvedon assets to the privately-held Cosette Pharmaceuticals could impact its future growth potential. The recent reverse stock split and CVR non-tradeable component also add uncertainty to the company's future performance, leading me to have a negative outlook on its stock.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.